Here are five takeaways:
1. The grant money will help the company fund its new spine surgery device, which involves a titanium plate securing spinal vertebrae during healing following surgery.
2. ReVivo President and CEO, Gary Mittleman, said the money will specifically fund the device’s testing on animals.
3. The device has not secured FDA approval, yet.
4. ReVivo will still need $500,000 to $800,000 to fund FDA testing and invest in products.
5. Albany (N.Y.) Medical Center spine surgeon Darryl DiRisio, MD, and biomedical engineers, Eric Ledet and Glenn Sanders, founded ReVivo Medical.
More articles on devices:
Regenexx receives US patent for stem cell procedure: 4 points
Smith & Nephew to acquire Blue Belt Technologies: 6 key notes
OrthoGrid creates new total hip replacement guide for HipGrid line: 5 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
